Skip to main content

Table 3 Events related to treatment with gemfibrozil

From: Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders

  Causal relationship Causal relationship
Probable Not established
General: weight loss  
Cardiac extrasystoles  
Gastrointestinal cholestatic jaundice pancreatitis
  hepatoma
  colitis
Central Nervous System dizziness confusion
Somnolence convulsions
Paresthesia syncope
peripheral neuritis  
decreased libido  
depression  
headache  
Eye blurred vision retina edema
Genitourinary impotence decreased male fertility
  renal dysfunction
Musculoskeletal myopathy  
myasthenia  
myalgia  
painful extremities  
arthralgia  
synovitis  
rhabdomyolysis  
Clinical Laboratories increased creatine positive antinuclear antibody
Phosphokinase  
increased bilirubin  
increased liver  
transaminases (AST, ALT)  
increased alkaline  
phosphatase  
Hematopoietic anemia thrombocytopenia
leukopenia  
bone marrow hypoplasia  
eosinophilia  
Immunologic angioedema anaphylaxis
laryngeal edema Lupus-like syndrome
urticarial vasculitis
Integumentary exfoliative dermatitis alopecia
Rash photosensitivity
dermatitis  
pruritus  
  1. SPC (Standard of Product Characteristics) of LOPID® (Gemfibrozil Tablets, USP) by Pfizer, Revised March 2016